aTyr Pharma Class Action Lawsuit (ATYR)
A failed-trial case following an 83% single-day collapse. Worth understanding why cases like this are among the hardest securities claims to win before you form expectations.
Active litigation. There is no claim form and no payout yet.
| Company | aTyr Pharma, Inc. (NASDAQ: ATYR) |
|---|---|
| Class period | 7 November 2024 – 12 September 2025 |
| Claims | §10(b) and §20(a), Securities Exchange Act of 1934 |
| Lead plaintiff deadline | 8 December 2025 — passed, and it does not affect your recovery |
| Trigger event | 12 September 2025 — efzofitimod Phase 3 miss; roughly 83% single-day share collapse |
| Can you file a claim? | Not yet. Realistically 2028–2030 if the case settles. |
Who this covers
Anyone who purchased or acquired aTyr Pharma securities between 7 November 2024 and 12 September 2025, inclusive.
What happened
aTyr's lead asset was efzofitimod, in development for pulmonary sarcoidosis. In September 2025 the company reported that the pivotal trial did not meet its primary endpoint. The stock lost roughly 83% of its value in a single session — one of the larger single-day biotech collapses of the year.
What the case alleges
The complaints allege that aTyr and certain executives made materially false and misleading statements about efzofitimod's efficacy and the state of the trial, causing investors to buy at artificially inflated prices, and that flaws bearing on the likelihood of success were not disclosed. These are allegations only. The company denies wrongdoing and the case has not yet faced a motion to dismiss.
The hard part of any failed-trial case
Clinical trial failures are the single most common trigger for biotech securities suits and among the hardest to win. Development-stage biotech is openly, disclosed-in-the-risk-factors probabilistic, and courts are generally unreceptive to arguments that amount to hindsight — that because the trial missed, the optimism beforehand must have been dishonest.
To survive dismissal, a case like this normally needs something more specific: internal data indicating a problem management knew about and did not disclose, statements that went beyond permissible optimism into concrete factual claims about results, a protocol or endpoint change that was concealed, or unusual insider selling during the class period. Whether the aTyr complaint has that will be decided on the motion to dismiss, and that ruling is the single event to watch.
This is not a reason to write the case off. It is a reason to calibrate expectations, and to be sceptical of any promotional material implying a payout is likely.
What to do now
- ✓Save your trade confirmations for every ATYR purchase and sale from November 2024 onward.
- ✓Do not act on the law firm press releases. You are already a class member if you bought in the class period; the "act by 8 December" messaging referred to the lead plaintiff role and is now moot.
- ✓Set an alert for the claim window rather than tracking the docket yourself.
Frequently Asked Questions
I bought after 12 September 2025, at the lower price. Am I covered?
No. The class period ends on the day the alleged truth emerged. Purchases after the collapse were made at a price that already reflected the news, so there is no fraud-related inflation to recover.
I bought before 7 November 2024 and still hold. Am I covered?
Generally no under the standard class definition, though the consolidated complaint could adjust the period. Keep your records regardless.
Does the 83% drop mean a big recovery?
Not by itself. The size of the drop sets the ceiling on damages, not the recovery. What matters is whether the case survives dismissal, and what insurance and company resources are available — which for a clinical-stage biotech that has just lost its lead asset can be limited.
Should I sell or hold ATYR because of the lawsuit?
Neither. Your potential claim rests on purchases already made during the class period. Subsequent trading does not create or destroy it.
See every settlement you qualify for
Tell SettleScout which brands you use and it matches you with open settlements, estimates your payouts, and reminds you before every deadline.
Free to download. Premium plans available.